Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P15313
UPID:
VATB1_HUMAN
Alternative names:
Endomembrane proton pump 58 kDa subunit; Vacuolar proton pump subunit B 1
Alternative UPACC:
P15313; Q53FY0; Q6P4H6
Background:
The V-type proton ATPase subunit B, kidney isoform, is a pivotal component of the V1 complex of vacuolar(H+)-ATPase (V-ATPase). This enzyme plays a crucial role in acidifying intracellular compartments and, in certain cells, the extracellular environment. It is essential for the assembly and activity of V-ATPase, facilitating proton secretion in renal intercalated cells for urinary acidification and is vital for olfactory function.
Therapeutic significance:
Given its critical role in renal distal tubular acidosis with progressive sensorineural hearing loss, targeting the V-type proton ATPase subunit B, kidney isoform, presents a promising avenue for therapeutic intervention. Understanding its function and the genetic variants affecting it could lead to novel treatments for this autosomal recessive disease.